The preclinical discovery and development of opicapone for the treatment of Parkinson’s disease
Autor
Ettcheto M.
Busquets O.
Sánchez-Lopez E.
Cano A.
Manzine P.R.
Verdaguer E.
Olloquequi J.
Auladell C.
Folch J.
Camins A.
Resumen
Introduction: Opicapone (OPC) is a well-established catechol-O-methyltransferase (COMT) inhibitor that is approved for the treatment of Parkinson’s disease (PD) associated with L-DOPA/L-amino acid decarboxylase inhibitor (DDI) therapy allowing for prolonged activity due to a more continuous supply of L-DOPA in the brain. Thus, OPC decreases fluctuation in L-DOPA plasma levels and favors more constant central dopaminergic receptor stimulation, thus improving PD symptomatology. Areas covered: This review evaluates the preclinical development, pharmacology, pharmacokinetics and safety profile of OPC. Data was extracted from published preclinical and clinical studies published on PUBMED and SCOPUS (Search period: 2000–2019). Clinical and post-marketing data are also evaluated. Expert opinion: OPC is a third generation COMT inhibitor with a novel structure. It has an efficacy and tolerability superior to its predecessors, tolcapone (TOL) and entacapone (ENT). It also provides a safe and simplified drug regimen that allows neurologists to individually adjust the existing daily administration of L-DOPA. OPC is indicated as an adjunctive therapy to L-DOPA/DDI in patients with PD and end-of-dose motor fluctuations who cannot be stabilized on those combinations. © 2020 Informa UK Limited, trading as Taylor & Francis Group.
Colecciones
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
Article
Role of brain c-Jun N-terminal kinase 2 in the control of the insulin receptor and its relationship with cognitive performance in a high-fat diet pre-clinical model (2020)
Busquets O.; Eritja À.; López B.M.; Ettcheto M.; Manzine P.R.; Castro-Torres R.D.; Verdaguer E.; Olloquequi J.; Vázquez-Carrera M.; Auladell C.; ... (Blackwell Publishing Ltd, 2019) -
Review
A metabolic perspective of late onset Alzheimer's disease (2020)
Ettcheto M.; Cano A.; Busquets O.; Manzine P.R.; Sánchez-López E.; Castro-Torres R.D.; Beas-Zarate C.; Verdaguer E.; García M.L.; Olloquequi J.; ... (Academic Press, 2019) -
Article
Epigallocatechin-3-Gallate (EGCG) Improves Cognitive Deficits Aggravated by an Obesogenic Diet Through Modulation of Unfolded Protein Response in APPswe/PS1dE9 Mice (2020)
Ettcheto M.; Cano A.; Manzine P.R.; Busquets O.; Verdaguer E.; Castro-Torres R.D.; García M.L.; Beas-Zarate C.; Olloquequi J.; Auladell C.; ... (Springer, 2020)